Showing 3,521 - 3,540 results of 17,899 for search 'Axact~', query time: 2.29s Refine Results
  1. 3521
  2. 3522
  3. 3523
  4. 3524
  5. 3525

    Use of computerised adaptive testing to reduce the number of items in patient-reported hip and knee outcome scores: an analysis of the NHS England National Patient-Reported Outcome Measures programme by Jose Maria Valderas, Andrew D Toms, Jonathan Peter Evans, Christopher Gibbons

    Published 2022-07-01
    “…We used a modern computational approach, known as computerised adaptive testing (CAT), to simulate individually tailored OHS and OKS assessment, with the goal of reducing the number of questions a patient must complete without compromising measurement accuracy.Methods We fit the 2018/2019 PROMs data to an item response theory (IRT) model. …”
    Get full text
    Article
  6. 3526
  7. 3527
  8. 3528

    El Plan para la Transformación de la Educación de Oaxaca (PTEO) como una educación formadora de resistencias decoloniales por la justicia socioambiental en Nuestra América by Mario Guzmán Guerrero

    Published 2023-07-01
    “…El escrito se sitúa en el estado de Oaxaca, México; espacio en donde convergen problemáticas socio-ambientales que provocan conflictos en el territorio y los seres vivos que coexisten. …”
    Get full text
    Article
  9. 3529
  10. 3530
  11. 3531
  12. 3532
  13. 3533
  14. 3534
  15. 3535
  16. 3536
  17. 3537
  18. 3538
  19. 3539

    Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study by Fei Wang, Yongjiu Wang, Bin Xiong, Zhenlin Yang, Jingfen Wang, Yumin Yao, Lixiang Yu, Qinye Fu, Liang Li, Qiang Zhang, Chao Zheng, Shuya Huang, Liyuan Liu, Chun Liu, Huaibo Sun, Beibei Mao, Dong-Xu Liu, Zhigang Yu

    Published 2025-01-01
    “…This prospective, multicentre, response-adapted study evaluated the efficacy and safety of adding pyrotinib to the neoadjuvant treatment of HER2-positive breast cancer patients with a poor response to initial docetaxel plus carboplatin and trastuzumab (TCbH). …”
    Get full text
    Article
  20. 3540